Cell line HMCB

Taxonomy

• Homo sapiens (Human)

Protein

• Tissue-type plasminogen activator / Homo sapiens    P00750

Source

• Skin of Body (UBERON_0002097)   HMCB (CVCL_3317)  

Reported structure

• N-Linked / Complex / GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)[GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
• N-Linked / Complex / GalNAc(b1-4)GlcNAc(b1-2)Man(a1-?)[HexNAc(b1-4)][Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
• N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-6)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
• N-Linked / Complex / GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
• N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-6)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
• N-Linked / Complex / GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(?1-6)]GlcNAc
• N-Linked / Complex / GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
• N-Linked / Complex / Gal(?1-?)GlcNAc(b1-2)Man(a1-?)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(?1-6)]GlcNAc+"+ NeuAc(a2-6)"
• N-Linked / Complex / NeuAc(a2-6)GalNAc(b1-4)GlcNAc(b1-2)Man(a1-?)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(?1-6)]GlcNAc
• N-Linked / Complex / Gal(b1-4)GlcNAc(b1-6)[GalNAc(b1-4)GlcNAc(b1-2)]Man(a1-6)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
• N-Linked / Complex / GalNAc(b1-4)GlcNAc(b1-2)[GalNAc(b1-4)GlcNAc(b1-?)]Man(a1-?)[GalNAc(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
• N-Linked / Complex / NeuAc(a2-6)Gal(?1-?)GlcNAc(b1-2)Man(a1-?)[NeuAc(a2-6)GalNAc(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(?1-6)]GlcNAc
• N-Linked / Complex / NeuAc(a2-6)GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)[NeuAc(a2-6)GalNAc(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(?1-6)]GlcNAc
• N-Linked / Hybrid / GalNAc(b1-4)GlcNAc(b1-2)Man(a1-3)[Man(a1-3)[Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
• O-Linked / No-core / Fuc

Composition

• dHex:1 (avg mass : 164.1583 )
• Hex:3 HexNAc:5 dHex:1 (avg mass : 1666.5605 )
• Hex:3 HexNAc:6 (avg mass : 1723.6125 )
• Hex:3 HexNAc:6 dHex:1 (avg mass : 1869.7555 )
• Hex:3 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2161.0134 )
• Hex:3 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 2452.2713 )
• Hex:3 HexNAc:8 dHex:1 (avg mass : 2276.1455 )
• Hex:4 HexNAc:5 (avg mass : 1682.5599 )
• Hex:4 HexNAc:5 dHex:1 (avg mass : 1828.7029 )
• Hex:4 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2119.9608 )
• Hex:4 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2411.2187 )
• Hex:4 HexNAc:7 dHex:1 (avg mass : 2235.0929 )
• Hex:5 HexNAc:4 (avg mass : 1641.5073 )

Disease

• Melanoma (DOID:1909)

Reference

• The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans. (1996 - Jaques A, Opdenakker G, Rademacher T, Dwek R, Zamze S) / Status : Reviewed
• Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain. (1991 - Harris R, Leonard C, Guzzetta A, Spellman M) / Status : Reviewed
• A novel sialylated N-acetylgalactosamine-containing oligosaccharide is the major complex-type structure present in Bowes melanoma tissue plasminogen activator. (1991 - Chan A, Morris H, Panico M, Etienne A, Rogers M, Gaffney P, Creighton-Kempsford L, Dell A) / Status : Reviewed

Reported glycosite

• Tissue-type plasminogen activator / Homo sapiens
  •        Undefined site
  •        Thr-96
  •        Asn-219
  •        Asn-483

Mass spectrometry observed peptide